Armistice Capital LLC Has $38.11 Million Position in Immunocore Holdings PLC Sponsored ADR $IMCR

Armistice Capital LLC grew its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 33.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,098,000 shares of the company’s stock after buying an additional 274,000 shares during the quarter. Armistice Capital LLC owned 2.17% of Immunocore worth $38,112,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IMCR. Royal Bank of Canada grew its holdings in shares of Immunocore by 45.1% during the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock valued at $1,306,000 after purchasing an additional 13,689 shares during the last quarter. Geode Capital Management LLC grew its holdings in Immunocore by 40.1% during the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company’s stock worth $1,632,000 after acquiring an additional 14,877 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Immunocore by 425.8% in the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock worth $4,601,000 after purchasing an additional 118,728 shares during the period. Sei Investments Co. acquired a new position in shares of Immunocore in the 2nd quarter worth approximately $983,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Immunocore by 108.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company’s stock worth $4,480,000 after purchasing an additional 74,128 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Trading Up 1.3%

Shares of IMCR opened at $28.55 on Thursday. The firm’s 50 day simple moving average is $29.45 and its 200 day simple moving average is $32.04. The company has a market capitalization of $1.45 billion, a P/E ratio of -51.91 and a beta of 0.74. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $27.56 and a 1-year high of $40.71.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The business had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. During the same period last year, the firm posted $0.10 earnings per share. Immunocore’s quarterly revenue was up 13.6% on a year-over-year basis. Sell-side analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IMCR has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Mizuho set a $38.00 price target on shares of Immunocore in a research report on Thursday, February 19th. Finally, Jefferies Financial Group lowered shares of Immunocore from a “buy” rating to a “hold” rating and cut their target price for the stock from $48.00 to $33.00 in a research report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $56.71.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.